has been appointed by Japanese electronics corporation, Panasonic, as its social content partner for its “SPORTS CHANGEMAKERS” global campaign.
As part of the partnership, the social video group will lead the creative execution on a series of videos across multiple platforms in four key markets: the US, Europe, China and Japan.
In 2019, Panasonic invited university students from these markets to participate in its 'Going Beyond Barriers' SPORTS CHANGEMAKERS competition where students were asked to identify barriers that exist in sports today and present a technology-based solution to them.
Brave Bison will work with one winning team from each key market to help tell their stories, including their upcoming journey to the Olympic games in 2021, where they will present their final idea to a panel of advisers.
The group will produce brand assets and bring on board four creators, one per market, ‘to tell their local CHANGEMAKER story in their own, unique way across multiple platforms and formats.’
Shares in Brave Bison were trading 5.56% higher at 1.425p on Tuesday morning.
Over the past year, Brave Bison has built a strong relationship with Panasonic, one of the world’s largest electronics companies and an official worldwide Olympic and Paralympic partner. Today’s partnership marks the first collaboration between the two companies.
"Brave Bison is one of the leading companies for video content creation and digital marketing around the world,” said Yasuhiro Fukuda, Panasonic project leader, Olympic and Paralympic Marketing Team at Panasonic.
“We have appointed them as our creating partner for social video content in our project because we were impressed by their cutting edge concept of social video creation and greatly respect their numerous global achievements,” added Fukuda.
Commenting on the partnership, Oliver Green, CEO at Brave Bison, said, "We're excited to be working with Panasonic on this global campaign, spanning multiple platforms and markets.
As a social content publisher that specialises in engaging youth audiences, we're eager to use our expertise to create easily-digestible content that tells these stories from start to finish."
Follow News & Updates from Brave Bison here:
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
Majid Shafiq, CEO of i3 Energy (AIM:I3E), and CFO, Graham Heath, discuss today’s follow-on deal to sell the Gain assets to Harvard Resources which will occur following the completion of the group’s previously announced C$80 million reverse takeover .
i3 Energy plc, an independent oil and gas company with assets and operations in the UK, Final Results for the year ended 31 December 2019 show significant operational progress for the pre-revenue company with net loss of £10.8m. To fund the Gain acquisition announced post period end in 2020, i3 is proposing to raise £30 million at a price of 5 pence per share, an 18% discount to the closing mid-price at which i3's shares suspended on 23 June 2020.
Oilex, the Operator of the PSC and on behalf of the JDPA joint venture, has reached amicable settlement with JPDA in East Timor with a settlement of US$0.8m payable in 2021 and 2022 financial years. The settlement amount is fully provided for in the FY19 accounts.
Avacta Group has entered into a collaboration with the Liverpool School of Tropical Medicine to clinically validate the rapid, saliva-based coronavirus antigen test that Avacta is developing in conjunction with Cytiva.
Shield Therapeutics said a reanalysis of the AEGIS-H2H study for its iron deficiency lead product Feraccru®/Accrufer® has confirmed the product as a credible alternative to IV therapy for patients with iron deficiency anaemia.